In the PM-2 K+CD14+ and PM-2 K+CD14− subsets, the percentages of M1-, M2a-, M2b-, and M2c-like macrophages were not significantly different between patients with HER2-positive breast cancer and those with HER2-negative breast cancer (c–j). This evidence concerns the gene ERBB2 and breast cancer.